These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 37798397)
41. Increasing haemoglobin oxygen affinity to prevent sickling: abnormal haemoglobin variants as models. Franklin IM; Huehns ER; Rosemeyer MA Br J Haematol; 1986 Oct; 64(2):319-29. PubMed ID: 3778826 [TBL] [Abstract][Full Text] [Related]
42. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Abdulmalik O; Safo MK; Chen Q; Yang J; Brugnara C; Ohene-Frempong K; Abraham DJ; Asakura T Br J Haematol; 2005 Feb; 128(4):552-61. PubMed ID: 15686467 [TBL] [Abstract][Full Text] [Related]
43. Established and experimental treatments for sickle cell disease. De Franceschi L; Corrocher R Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275 [TBL] [Abstract][Full Text] [Related]
44. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Dufu K; Alt C; Strutt S; Partridge J; Tang T; Siu V; Liao-Zou H; Rademacher P; Williams AT; Muller CR; Geng X; Pochron MP; Dang AN; Cabrales P; Li Z; Oksenberg D; Cathers BE Br J Haematol; 2023 Jul; 202(1):173-183. PubMed ID: 36960712 [TBL] [Abstract][Full Text] [Related]
45. Doping control approach: Identification of equine in vitro metabolites of voxelotor (GBT440), a hemoglobin S polymerization inhibitor. Subhahar MB; Karakka Kal AK; Philip M; Muhammed Ajeebsanu M; Karatt TK; Perwad Z Rapid Commun Mass Spectrom; 2024 Jan; 38(2):e9671. PubMed ID: 38124165 [TBL] [Abstract][Full Text] [Related]
46. High-throughput assessment of hemoglobin polymer in single red blood cells from sickle cell patients under controlled oxygen tension. Di Caprio G; Schonbrun E; Gonçalves BP; Valdez JM; Wood DK; Higgins JM Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25236-25242. PubMed ID: 31767751 [TBL] [Abstract][Full Text] [Related]
47. 5'-deoxypyridoxal as a potential anti-sickling agent. Benesch R; Benesch RE; Edalji R; Suzuki T Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1721-3. PubMed ID: 266212 [TBL] [Abstract][Full Text] [Related]
48. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Wood KC; Granger DN Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642 [TBL] [Abstract][Full Text] [Related]
49. Sickle cell anemia and antisickling agents then and now. Mehanna AS Curr Med Chem; 2001 Feb; 8(2):79-88. PubMed ID: 11172667 [TBL] [Abstract][Full Text] [Related]
50. Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease. Li Q; Henry ER; Hofrichter J; Smith JF; Cellmer T; Dunkelberger EB; Metaferia BB; Jones-Straehle S; Boutom S; Christoph GW; Wakefield TH; Link ME; Staton D; Vass ER; Miller JL; Hsieh MM; Tisdale JF; Eaton WA Proc Natl Acad Sci U S A; 2017 Jan; 114(5):E689-E696. PubMed ID: 28096387 [TBL] [Abstract][Full Text] [Related]
51. Targeting sickle cell disease root-cause pathophysiology with small molecules. Saunthararajah Y Haematologica; 2019 Sep; 104(9):1720-1730. PubMed ID: 31399526 [TBL] [Abstract][Full Text] [Related]
52. Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease. Vunnam N; Hansen S; Williams DC; Been MO; Lo CH; Pandey AK; Paulson CN; Rohde JA; Thomas DD; Sachs JN; Wood DK Biomacromolecules; 2022 Sep; 23(9):3822-3830. PubMed ID: 35944154 [TBL] [Abstract][Full Text] [Related]
53. Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice. Dufu K; Williams AT; Muller CR; Walser CM; Lucas A; Eaker AM; Alt C; Cathers BE; Oksenberg D; Cabrales P Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H400-H411. PubMed ID: 34213392 [TBL] [Abstract][Full Text] [Related]
54. Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease. Ahmed TA; El-Say KM; Abd-Allah FI; Omar AM; El-Araby ME; Muhammad YA; Pagare PP; Zhang Y; Mohmmad KA; Abdulmalik O; Safo MK Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452107 [TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease. Hutchaleelaha A; Patel M; Washington C; Siu V; Allen E; Oksenberg D; Gretler DD; Mant T; Lehrer-Graiwer J Br J Clin Pharmacol; 2019 Jun; 85(6):1290-1302. PubMed ID: 30743314 [TBL] [Abstract][Full Text] [Related]
56. Specific chemical modifications in the beta-cleft site of hemoglobin. Potential anti-sickling agents with hybrid functionalities. Klotz IM; Haney DN; Wood LE J Biol Chem; 1985 Dec; 260(30):16215-23. PubMed ID: 4066708 [TBL] [Abstract][Full Text] [Related]